Courier Health Raises $50M Series B From Oak HC/FT

Key Takeaways

• Courier Health raised $50M Series B led by Oak HC/FT
• Platform unifies pharmacy, hub, claims, and EHR data
• Clients report over 15% increase in patient therapy starts
• 6‑month persistency improves 10‑12% after implementation
• Team productivity jumps five to seven times with the solution

Pulse Analysis

Specialty medicines account for a growing share of U.S. healthcare spend, yet adherence remains a chronic problem—roughly 30% of patients never begin therapy and up to 70% discontinue within a year. The root cause is operational: fragmented data across legacy CRMs, spreadsheets, and siloed hub portals hampers coordinated care. As biopharma invests heavily in patient access programs, the industry seeks a unified view of each patient’s journey to reduce drop‑off and improve outcomes.

Courier Health addresses this gap with a cloud‑native platform that ingests real‑time feeds from specialty pharmacies, hub networks, claims processors, electronic health records, and field teams. By stitching these streams into a single, compliant patient record, the system surfaces risk alerts and automates outreach, enabling teams to act swiftly. Early deployments have delivered measurable gains—more than a 15% rise in therapy initiations, 10‑12% higher six‑month persistency, and a five‑to‑seven‑fold increase in staff productivity—demonstrating the tangible value of data integration in a high‑stakes therapeutic arena.

The $50 million Series B, led by Oak HC/FT, not only validates Courier Health’s model but also signals broader market appetite for patient‑centric health‑tech. With the new capital, the company plans to scale its engineering resources, deepen AI‑driven analytics, and broaden its go‑to‑market footprint across larger biopharma partners. As payers and manufacturers increasingly tie reimbursement to real‑world outcomes, solutions that can reliably track and improve patient adherence are poised to become essential infrastructure, positioning Courier Health as a strategic asset in the evolving specialty drug ecosystem.